Aarti Drugs
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Aarti Drugs said the Supreme Court dismissed the GST Department’s special-leave petition against a Bombay High Court order that had set aside a tax order against the company. The dispute followed a show-cause notice proposing ₹230.70 crore of IGST, interest and penalties for FY2017-18 to FY2021-22; the adjudicating authority ultimately demanded repayment of ₹20.72 crore in IGST refunds, plus interest and a ₹20.72 crore penalty, while dropping ₹209.98 crore. The Bombay High Court had overturned that order, and the Supreme Court’s dismissal disposed of the matter. Aarti Drugs said the outcome had no financial, operational or other impact on its activities. The company reported FY26 consolidated revenue of about ₹2,565 crore and net debt of ₹566 crore.
Powered by Tijori
Aarti Drugs said the Supreme Court dismissed the GST Department’s special-leave petition against a Bombay High Court order that had set aside a tax order against the company. The dispute followed a show-cause notice proposing ₹230.70 crore of IGST, interest and penalties for FY2017-18 to FY2021-22; the adjudicating authority ultimately demanded repayment of ₹20.72 crore in IGST refunds, plus interest and a ₹20.72 crore penalty, while dropping ₹209.98 crore. The Bombay High Court had overturned that order, and the Supreme Court’s dismissal disposed of the matter. Aarti Drugs said the outcome had no financial, operational or other impact on its activities. The company reported FY26 consolidated revenue of about ₹2,565 crore and net debt of ₹566 crore.
Powered by Tijori
Aarti Drugs Limited announced a leadership transition, with the board approving Rashesh C. Gogri's elevation to Chairman in addition to his role as Managing Director and Adhish P. Patil's appointment as Managing Director, both effective October 1, 2026. Prakash M. Patil will retire as Chairman, Managing Director and Chief Executive Officer at the close of business on September 30, 2026, and will remain available for guidance and strategic support. The company, one of India's leading active pharmaceutical ingredient makers with 14 manufacturing sites, published its June-quarter results the same day, showing consolidated revenue of ₹702.8 crore, up 19% year on year, and profit after tax of ₹50.1 crore. It is part of the $6 billion Aarti Group of Industries.
Powered by Tijori
Aarti Drugs Limited announced a leadership transition, with the board approving Rashesh C. Gogri's elevation to Chairman in addition to his role as Managing Director and Adhish P. Patil's appointment as Managing Director, both effective October 1, 2026. Prakash M. Patil will retire as Chairman, Managing Director and Chief Executive Officer at the close of business on September 30, 2026, and will remain available for guidance and strategic support. The company, one of India's leading active pharmaceutical ingredient makers with 14 manufacturing sites, published its June-quarter results the same day, showing consolidated revenue of ₹702.8 crore, up 19% year on year, and profit after tax of ₹50.1 crore. It is part of the $6 billion Aarti Group of Industries.
Powered by Tijori
Aarti Drugs' Chairman, Managing Director and Chief Executive Officer Prakash M. Patil will retire on September 30, 2026, before the expiry of his term in May 2027. Rashesh C. Gogri, the company's managing director, will become Chairman from October 1, and Adhish P. Patil — the outgoing chairman's son and currently chief financial officer — was appointed Managing Director for five years. The changes were approved alongside the company's June-quarter results, in which consolidated revenue rose 19% year on year to ₹702.8 crore. The company has been grappling with operational disruptions, including a retrofit shutdown at its Tarapur salicylic acid plant and a Gujarat pollution board closure order on its Sayakha amines unit that takes effect on August 2.
Powered by Tijori
Aarti Drugs' Chairman, Managing Director and Chief Executive Officer Prakash M. Patil will retire on September 30, 2026, before the expiry of his term in May 2027. Rashesh C. Gogri, the company's managing director, will become Chairman from October 1, and Adhish P. Patil — the outgoing chairman's son and currently chief financial officer — was appointed Managing Director for five years. The changes were approved alongside the company's June-quarter results, in which consolidated revenue rose 19% year on year to ₹702.8 crore. The company has been grappling with operational disruptions, including a retrofit shutdown at its Tarapur salicylic acid plant and a Gujarat pollution board closure order on its Sayakha amines unit that takes effect on August 2.
Powered by Tijori
July 31 (Reuters) - Aarti Drugs Ltd ADRG.NS:
JUNE-QUARTER CONSOL NET PROFIT 501.7 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 7.03 BILLION RUPEES
Source text: [ID:]
Further company coverage: ADRG.NS
(([email protected];))
July 31 (Reuters) - Aarti Drugs Ltd ADRG.NS:
JUNE-QUARTER CONSOL NET PROFIT 501.7 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 7.03 BILLION RUPEES
Source text: [ID:]
Further company coverage: ADRG.NS
(([email protected];))
May 15 (Reuters) - Aarti Drugs Ltd ADRG.NS:
AARTI DRUGS LTD MARCH-QUARTER CONSOL PROFIT 552.6 MILLION RUPEES
AARTI DRUGS LTD MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 7.2 BILLION RUPEES
Source text: [ID:]
Further company coverage: ADRG.NS
(([email protected];))
May 15 (Reuters) - Aarti Drugs Ltd ADRG.NS:
AARTI DRUGS LTD MARCH-QUARTER CONSOL PROFIT 552.6 MILLION RUPEES
AARTI DRUGS LTD MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 7.2 BILLION RUPEES
Source text: [ID:]
Further company coverage: ADRG.NS
(([email protected];))
Feb 3 (Reuters) - Aarti Drugs Ltd ADRG.NS:
AARTI DRUGS DEC-QUARTER CONSOL NET PROFIT 405.4 MILLION RUPEES
AARTI DRUGS LTD - DECLARED INTERIM DIVIDEND OF 2 RUPEES PER SHARE
AARTI DRUGS DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 6.02 BILLION RUPEES
Source text: ID:nnAZN4S8KO5
Further company coverage: ADRG.NS
(([email protected];))
Feb 3 (Reuters) - Aarti Drugs Ltd ADRG.NS:
AARTI DRUGS DEC-QUARTER CONSOL NET PROFIT 405.4 MILLION RUPEES
AARTI DRUGS LTD - DECLARED INTERIM DIVIDEND OF 2 RUPEES PER SHARE
AARTI DRUGS DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 6.02 BILLION RUPEES
Source text: ID:nnAZN4S8KO5
Further company coverage: ADRG.NS
(([email protected];))
Sept 4 (Reuters) - Aarti Drugs Ltd ADRG.NS:
AARTI DRUGS LTD - COMMERCIALIZATION OF MANUFACTURING PLANT LOCATED AT SAYAKHA
Source text: ID:nBSE3KrdLN
Further company coverage: ADRG.NS
(([email protected];;))
Sept 4 (Reuters) - Aarti Drugs Ltd ADRG.NS:
AARTI DRUGS LTD - COMMERCIALIZATION OF MANUFACTURING PLANT LOCATED AT SAYAKHA
Source text: ID:nBSE3KrdLN
Further company coverage: ADRG.NS
(([email protected];;))
** Shares of Aarti Drugs ADRG.NS rise as much as 7.5% to 562 rupees, highest since September 6
** Pharmaceutical co posts a 62.2% Y/Y rise in June quarter consolidated net profit; rev from ops up 6.3 Y/Y
** Trading volume exceeds 1.6 mln shares, 2.6x 30-day moving avg
** Stock up 22% YTD
(Reporting by Rudra Pratap Singh in Bengaluru)
** Shares of Aarti Drugs ADRG.NS rise as much as 7.5% to 562 rupees, highest since September 6
** Pharmaceutical co posts a 62.2% Y/Y rise in June quarter consolidated net profit; rev from ops up 6.3 Y/Y
** Trading volume exceeds 1.6 mln shares, 2.6x 30-day moving avg
** Stock up 22% YTD
(Reporting by Rudra Pratap Singh in Bengaluru)
March 7 (Reuters) - Aarti Drugs Ltd ADRG.NS:
AARTI DRUGS LTD - RECEIVES ADMINISTRATIVE WARNING LETTER FROM SEBI
AARTI DRUGS LTD - WARNING ISSUED FOR VIOLATION OF INSIDER TRADING REGULATIONS
Source text: ID:nBSE2bv5vK
Further company coverage: ADRG.NS
(([email protected];))
March 7 (Reuters) - Aarti Drugs Ltd ADRG.NS:
AARTI DRUGS LTD - RECEIVES ADMINISTRATIVE WARNING LETTER FROM SEBI
AARTI DRUGS LTD - WARNING ISSUED FOR VIOLATION OF INSIDER TRADING REGULATIONS
Source text: ID:nBSE2bv5vK
Further company coverage: ADRG.NS
(([email protected];))
March 6 (Reuters) - Aarti Drugs Ltd ADRG.NS:
AARTI DRUGS LTD - SEBI ISSUES ADMINISTRATIVE WARNING TO CO'S COMPLIANCE OFFICER, COMPANY SECRETARY
AARTI DRUGS LTD - NO IMPACT ON FINANCIAL, OPERATIONAL OR OTHER ACTIVITIES
Source text: ID:nBSE1T64wJ
Further company coverage: ADRG.NS
(([email protected];))
March 6 (Reuters) - Aarti Drugs Ltd ADRG.NS:
AARTI DRUGS LTD - SEBI ISSUES ADMINISTRATIVE WARNING TO CO'S COMPLIANCE OFFICER, COMPANY SECRETARY
AARTI DRUGS LTD - NO IMPACT ON FINANCIAL, OPERATIONAL OR OTHER ACTIVITIES
Source text: ID:nBSE1T64wJ
Further company coverage: ADRG.NS
(([email protected];))
** Shares of Aarti Drugs ADRG.NS jump 13% to 433 rupees, in a broader weak market
** US FDA lifts import restrictions imposed following inspection at co's active pharmaceutical ingredient (API) manufacturing facility
** Following the order, ADRG can now export its API products to the US
** Nifty Pharma Index .NIPHARM is down 3% on Trump tariff woes; ADRG is not part of the index
** ADRG trading vols at 3.5x their 30-day avg
** Stock is down around 13% YTD
(Reporitng by Nishit Navin)
(([email protected];))
** Shares of Aarti Drugs ADRG.NS jump 13% to 433 rupees, in a broader weak market
** US FDA lifts import restrictions imposed following inspection at co's active pharmaceutical ingredient (API) manufacturing facility
** Following the order, ADRG can now export its API products to the US
** Nifty Pharma Index .NIPHARM is down 3% on Trump tariff woes; ADRG is not part of the index
** ADRG trading vols at 3.5x their 30-day avg
** Stock is down around 13% YTD
(Reporitng by Nishit Navin)
(([email protected];))
Feb 3 (Reuters) - Aarti Drugs Ltd ADRG.NS:
AARTI DRUGS LTD - TO ACQUIRE 26.25% EQUITY IN PRO-ZEAL GREEN POWER NINE
AARTI DRUGS LTD - TOTAL ACQUISITION COST 80.5 MILLION RUPEES
Source text: ID:nBSE43b8YN
Further company coverage: ADRG.NS
(([email protected];;))
Feb 3 (Reuters) - Aarti Drugs Ltd ADRG.NS:
AARTI DRUGS LTD - TO ACQUIRE 26.25% EQUITY IN PRO-ZEAL GREEN POWER NINE
AARTI DRUGS LTD - TOTAL ACQUISITION COST 80.5 MILLION RUPEES
Source text: ID:nBSE43b8YN
Further company coverage: ADRG.NS
(([email protected];;))
Jan 29 (Reuters) - Aarti Drugs Ltd ADRG.NS:
AARTI DRUGS DEC-QUARTER CONSOL NET PROFIT 370.5 MILLION RUPEES
AARTI DRUGS DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 5.57 BILLION RUPEES
Source text: [ID:]
Further company coverage: ADRG.NS
(([email protected];))
Jan 29 (Reuters) - Aarti Drugs Ltd ADRG.NS:
AARTI DRUGS DEC-QUARTER CONSOL NET PROFIT 370.5 MILLION RUPEES
AARTI DRUGS DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 5.57 BILLION RUPEES
Source text: [ID:]
Further company coverage: ADRG.NS
(([email protected];))
** Shares of Aarti Drugs ADRG.NS fall 2.7% to 471.60 rupees
** The pharmaceutical company reported a 12% dip Y/Y in Q2 consol profit, revenue falls 7% Y/Y
** Relative strength index falls to 20.2, suggesting that the stock might be oversold - LSEG data
** ADRG falls for 13th straight session
** Stock down ~4% YTD
(Reporting by Vijay Malkar)
(([email protected];))
** Shares of Aarti Drugs ADRG.NS fall 2.7% to 471.60 rupees
** The pharmaceutical company reported a 12% dip Y/Y in Q2 consol profit, revenue falls 7% Y/Y
** Relative strength index falls to 20.2, suggesting that the stock might be oversold - LSEG data
** ADRG falls for 13th straight session
** Stock down ~4% YTD
(Reporting by Vijay Malkar)
(([email protected];))
** Shares of drugmaker Aarti Drugs ADRG.NS rise 2% to 525 rupees
** Co said UK's Medicines and Healthcare products Regulatory Agency issued GMP compliance certificate for unit's manufacturing facility in Himachal Pradesh
** Stock set to snap four straight weeks of losses, gained ~2% this week
** Stock has risen 7.7% YTD
(Reporting by Yagnoseni Das in Bengaluru)
(([email protected];))
** Shares of drugmaker Aarti Drugs ADRG.NS rise 2% to 525 rupees
** Co said UK's Medicines and Healthcare products Regulatory Agency issued GMP compliance certificate for unit's manufacturing facility in Himachal Pradesh
** Stock set to snap four straight weeks of losses, gained ~2% this week
** Stock has risen 7.7% YTD
(Reporting by Yagnoseni Das in Bengaluru)
(([email protected];))
Oct 3 (Reuters) - Aarti Drugs Ltd ADRG.NS:
RECEIPT OF GMP CERTIFICATE FROM UK-MHRA FOR MANUFACTURING FACILITY OF UNIT
Source text for Eikon: ID:nBSE8NWNnW
Further company coverage: ADRG.NS
(([email protected];;))
Oct 3 (Reuters) - Aarti Drugs Ltd ADRG.NS:
RECEIPT OF GMP CERTIFICATE FROM UK-MHRA FOR MANUFACTURING FACILITY OF UNIT
Source text for Eikon: ID:nBSE8NWNnW
Further company coverage: ADRG.NS
(([email protected];;))
** Shares of Aarti Drugs ADRG.NS fall as much as 2% to 510.20 rupees
** Drugmaker says its API manufacturing facility at Tarapur in Maharashtra, has received seven inspectional observations in Form 483 from the U.S. FDA
** A Form 483 is a type of agency report containing observations that FDA inspectors deem to be objectionable
** Stock on track for a third consecutive session of loss
** Stock last down 1%, cutting YTD gains to 5.4%
(Reporting by Ashish Chandra in Bengaluru)
(([email protected] (+91 7982114624))
** Shares of Aarti Drugs ADRG.NS fall as much as 2% to 510.20 rupees
** Drugmaker says its API manufacturing facility at Tarapur in Maharashtra, has received seven inspectional observations in Form 483 from the U.S. FDA
** A Form 483 is a type of agency report containing observations that FDA inspectors deem to be objectionable
** Stock on track for a third consecutive session of loss
** Stock last down 1%, cutting YTD gains to 5.4%
(Reporting by Ashish Chandra in Bengaluru)
(([email protected] (+91 7982114624))
Sept 25 (Reuters) - Aarti Drugs Ltd ADRG.NS:
RECEIVED 7 INSPECTIONAL OBSERVATIONS IN FORM 483 FROM US FDA
US FDA INSPECTION WAS AT API MANUFACTURING FACILITY AT TARAPUR
Source text for Eikon: ID:nNSEHbm5S
Further company coverage: ADRG.NS
(([email protected];;))
Sept 25 (Reuters) - Aarti Drugs Ltd ADRG.NS:
RECEIVED 7 INSPECTIONAL OBSERVATIONS IN FORM 483 FROM US FDA
US FDA INSPECTION WAS AT API MANUFACTURING FACILITY AT TARAPUR
Source text for Eikon: ID:nNSEHbm5S
Further company coverage: ADRG.NS
(([email protected];;))
Aug 26 (Reuters) - Aarti Drugs Ltd ADRG.NS:
AARTI DRUGS - APPROVED BUYBACK OF SHARES WORTH UPTO 598.5 MILLION RUPEES
AARTI DRUGS LTD- BUYBACK PRICE OF 900 RUPEES PER SHARE
AARTI DRUGS - BUYBACK THROUGH TENDER OFFER ROUTE
AARTI DRUGS LTD- INTENTION OF PROMOTER GROUP TO PARTICIPATE IN PROPOSED BUYBACK
Further company coverage: ADRG.NS
(([email protected];))
Aug 26 (Reuters) - Aarti Drugs Ltd ADRG.NS:
AARTI DRUGS - APPROVED BUYBACK OF SHARES WORTH UPTO 598.5 MILLION RUPEES
AARTI DRUGS LTD- BUYBACK PRICE OF 900 RUPEES PER SHARE
AARTI DRUGS - BUYBACK THROUGH TENDER OFFER ROUTE
AARTI DRUGS LTD- INTENTION OF PROMOTER GROUP TO PARTICIPATE IN PROPOSED BUYBACK
Further company coverage: ADRG.NS
(([email protected];))
** Shares of India's Aarti Drugs ADRG.NS jump 8.2% to 577.7 rupees
** Drugmaker says its board will consider buyback of shares on Aug. 26
** ADRG on track for fourth straight session of gains
** Day's rise takes YTD gains to 17.5%
(Reporting by Hritam Mukherjee in Bengaluru)
(([email protected];))
** Shares of India's Aarti Drugs ADRG.NS jump 8.2% to 577.7 rupees
** Drugmaker says its board will consider buyback of shares on Aug. 26
** ADRG on track for fourth straight session of gains
** Day's rise takes YTD gains to 17.5%
(Reporting by Hritam Mukherjee in Bengaluru)
(([email protected];))
Aug 1 (Reuters) - Aarti Drugs Ltd ADRG.NS:
US FDA CONDUCTED INSPECTION AT UNIT'S MANUFACTURING FACILITY AT BADDI
PINNACLE IS IN RECEIPT OF ESTABLISHMENT INSPECTION REPORT
Source text for Eikon: ID:nNSEHby3R
Further company coverage: ADRG.NS
(([email protected];))
Aug 1 (Reuters) - Aarti Drugs Ltd ADRG.NS:
US FDA CONDUCTED INSPECTION AT UNIT'S MANUFACTURING FACILITY AT BADDI
PINNACLE IS IN RECEIPT OF ESTABLISHMENT INSPECTION REPORT
Source text for Eikon: ID:nNSEHby3R
Further company coverage: ADRG.NS
(([email protected];))
** Shares of Aarti Drugs ADRG.NS gain ~2% to 512.55 rupees
** Drugmaker said US FDA concluded inspection at ADRG's manufacturing facility in Himachal Pradesh
** ADRG received establishment inspection report after conclusion of inspection
** Stock up ~5% YTD, set for second straight annual gain
(Reporting by Kashish Tandon in Bengaluru)
** Shares of Aarti Drugs ADRG.NS gain ~2% to 512.55 rupees
** Drugmaker said US FDA concluded inspection at ADRG's manufacturing facility in Himachal Pradesh
** ADRG received establishment inspection report after conclusion of inspection
** Stock up ~5% YTD, set for second straight annual gain
(Reporting by Kashish Tandon in Bengaluru)
July 29 (Reuters) - Aarti Drugs Ltd ADRG.NS:
US FDA EIR AT MANUFACTURING FACILITY OF UNIT AT BADDI, HIMACHAL PRADESH
GETS EIR FROM USFDA CONCLUDING INSPECTION AS CLOSED
Source text for Eikon: ID:nNSE4XTgJD
Further company coverage: ADRG.NS
(([email protected];))
July 29 (Reuters) - Aarti Drugs Ltd ADRG.NS:
US FDA EIR AT MANUFACTURING FACILITY OF UNIT AT BADDI, HIMACHAL PRADESH
GETS EIR FROM USFDA CONCLUDING INSPECTION AS CLOSED
Source text for Eikon: ID:nNSE4XTgJD
Further company coverage: ADRG.NS
(([email protected];))
July 26 (Reuters) - Aarti Drugs Ltd ADRG.NS:
AARTI DRUGS - IN FY25, ANTICIPATE IMPROVEMENT IN MARGINS DRIVEN BY GROWTH IN EXPORT SALES
AARTI DRUGS - ANTICIPATE TOTAL CAPEX OF 2 BILLION RUPEES FOR FY25
Further company coverage: ADRG.NS
(([email protected];))
July 26 (Reuters) - Aarti Drugs Ltd ADRG.NS:
AARTI DRUGS - IN FY25, ANTICIPATE IMPROVEMENT IN MARGINS DRIVEN BY GROWTH IN EXPORT SALES
AARTI DRUGS - ANTICIPATE TOTAL CAPEX OF 2 BILLION RUPEES FOR FY25
Further company coverage: ADRG.NS
(([email protected];))
July 17 (Reuters) - Aarti Drugs Ltd ADRG.NS:
CO DIRECTED TO VOLUNTARILY STOP MANUFACTURING PARTICULAR PRODUCT AT MAHARASHTRA PLANT
Source text for Eikon: ID:nNSE3RMX01
Further company coverage: ADRG.NS
(([email protected];))
July 17 (Reuters) - Aarti Drugs Ltd ADRG.NS:
CO DIRECTED TO VOLUNTARILY STOP MANUFACTURING PARTICULAR PRODUCT AT MAHARASHTRA PLANT
Source text for Eikon: ID:nNSE3RMX01
Further company coverage: ADRG.NS
(([email protected];))
June 18 (Reuters) - Aarti Drugs Ltd ADRG.NS:
AARTI DRUGS LTD - FIRE OCCURRED AT N-198 UNIT LOCATED AT TARAPUR, MAHARASHTRA
AARTI DRUGS LTD- FIRE WAS BROUGHT UNDER CONTROL IMMEDIATELY
AARTI DRUGS LTD- HOWEVER PRODUCTION OPERATION OF SAID UNIT HAS BEEN TEMPORARILY DISRUPTED
AARTI DRUGS LTD - NO LOSS OF LIFE OR INJURIES REPORTED DUE TO FIRE
AARTI DRUGS LTD - COMPANY PROJECTS NO MATERIAL IMPACT ON FINANCIALS AND OPERATIONS OF BUSINESS
AARTI DRUGS LTD- UNIT HAS ADEQUATE INSURANCE COVERAGE
AARTI DRUGS LTD - DIFFICULT TO ASSESS FINANCIAL IMPACT ON COMPANY PURSUANT TO INCIDENT
AARTI DRUGS LTD - COMPANY PROJECTS NO MATERIAL IMPACT ON FINANCIALS AND OPERATIONS OF BUSINESS
Source text for Eikon: ID:nBSE80LMgJ
Further company coverage: ADRG.NS
(([email protected];))
June 18 (Reuters) - Aarti Drugs Ltd ADRG.NS:
AARTI DRUGS LTD - FIRE OCCURRED AT N-198 UNIT LOCATED AT TARAPUR, MAHARASHTRA
AARTI DRUGS LTD- FIRE WAS BROUGHT UNDER CONTROL IMMEDIATELY
AARTI DRUGS LTD- HOWEVER PRODUCTION OPERATION OF SAID UNIT HAS BEEN TEMPORARILY DISRUPTED
AARTI DRUGS LTD - NO LOSS OF LIFE OR INJURIES REPORTED DUE TO FIRE
AARTI DRUGS LTD - COMPANY PROJECTS NO MATERIAL IMPACT ON FINANCIALS AND OPERATIONS OF BUSINESS
AARTI DRUGS LTD- UNIT HAS ADEQUATE INSURANCE COVERAGE
AARTI DRUGS LTD - DIFFICULT TO ASSESS FINANCIAL IMPACT ON COMPANY PURSUANT TO INCIDENT
AARTI DRUGS LTD - COMPANY PROJECTS NO MATERIAL IMPACT ON FINANCIALS AND OPERATIONS OF BUSINESS
Source text for Eikon: ID:nBSE80LMgJ
Further company coverage: ADRG.NS
(([email protected];))
May 3 (Reuters) - Aarti Drugs Ltd ADRG.NS:
AARTI DRUGS MARCH-QUARTER CONSOL NET PROFIT 473.7 MILLION RUPEES VERSUS PROFIT 560.9 MILLION RUPEES
AARTI DRUGS MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 6.2 BILLION RUPEES VERSUS 7.42 BILLION RUPEES
Source text for Eikon: ID:nBSE3PdjKR
Further company coverage: ADRG.NS
(([email protected];;))
May 3 (Reuters) - Aarti Drugs Ltd ADRG.NS:
AARTI DRUGS MARCH-QUARTER CONSOL NET PROFIT 473.7 MILLION RUPEES VERSUS PROFIT 560.9 MILLION RUPEES
AARTI DRUGS MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 6.2 BILLION RUPEES VERSUS 7.42 BILLION RUPEES
Source text for Eikon: ID:nBSE3PdjKR
Further company coverage: ADRG.NS
(([email protected];;))
April 23 (Reuters) - Aarti Drugs Ltd ADRG.NS:
USFDA HAS INSPECTED FORMULATIONS MANUFACTURING FACILITY OF OUR SUBSIDIARY
COMPANY HAS RECEIVED 5 INSPECTIONAL OBSERVATIONS IN FORM 483
NONE OF OBSERVATIONS RECEIVED ARE RELATED TO DATA INTEGRITY
THERE IS NO IMPACT ON FINANCIAL, OPERATION OR OTHER ACTIVITIES OF CO
Source text for Eikon: ID:nBSE4Tqs60
Further company coverage: ADRG.NS
(([email protected];))
April 23 (Reuters) - Aarti Drugs Ltd ADRG.NS:
USFDA HAS INSPECTED FORMULATIONS MANUFACTURING FACILITY OF OUR SUBSIDIARY
COMPANY HAS RECEIVED 5 INSPECTIONAL OBSERVATIONS IN FORM 483
NONE OF OBSERVATIONS RECEIVED ARE RELATED TO DATA INTEGRITY
THERE IS NO IMPACT ON FINANCIAL, OPERATION OR OTHER ACTIVITIES OF CO
Source text for Eikon: ID:nBSE4Tqs60
Further company coverage: ADRG.NS
(([email protected];))
** Shares of Aarti Drugs ADRG.NS rise 3.9% to 454.7 rupees; last up ~3.2%
** The Gujarat Pollution Control Board (GPCB) permanently revoked a closure order issued for co's Sarigam Plant, dated March 30, 2022
** The plant manufactures diabetes drug metformin hydrochloride; a trial revocation of the closure was issued on April 30, 2022
** Stock on track to snap two consecutive session of losses
** Still, stock eyes fourth consecutive week of losses
** Stock down nearly 7.6% YTD vs 9.9% rise in Nifty pharma index .NIPHARM
(Reporting by Navamya Ganesh Acharya in Bengaluru)
(([email protected]; +91 8805175330 ;))
** Shares of Aarti Drugs ADRG.NS rise 3.9% to 454.7 rupees; last up ~3.2%
** The Gujarat Pollution Control Board (GPCB) permanently revoked a closure order issued for co's Sarigam Plant, dated March 30, 2022
** The plant manufactures diabetes drug metformin hydrochloride; a trial revocation of the closure was issued on April 30, 2022
** Stock on track to snap two consecutive session of losses
** Still, stock eyes fourth consecutive week of losses
** Stock down nearly 7.6% YTD vs 9.9% rise in Nifty pharma index .NIPHARM
(Reporting by Navamya Ganesh Acharya in Bengaluru)
(([email protected]; +91 8805175330 ;))
Jan 30 (Reuters) - Aarti Drugs Ltd ADRG.NS:
INITIATING COMMERCIAL PRODUCTION OF DERMATOLOGY PRODUCT AT FACILITY IN TARAPUR, MAHARASHTRA
TOTAL INVESTMENT REQUIREMENT 1.5-2 BILLION RUPEES
FACILITY WILL HAVE TOTAL OPERATIONAL CAPACITY OF 24,000 MTPA
Source text for Eikon: ID:nBSE2h6p7B
Further company coverage: ADRG.NS
(([email protected];))
Jan 30 (Reuters) - Aarti Drugs Ltd ADRG.NS:
INITIATING COMMERCIAL PRODUCTION OF DERMATOLOGY PRODUCT AT FACILITY IN TARAPUR, MAHARASHTRA
TOTAL INVESTMENT REQUIREMENT 1.5-2 BILLION RUPEES
FACILITY WILL HAVE TOTAL OPERATIONAL CAPACITY OF 24,000 MTPA
Source text for Eikon: ID:nBSE2h6p7B
Further company coverage: ADRG.NS
(([email protected];))
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Aarti Drugs do?
Aarti Drugs Limited, a key player in the pharmaceutical industry, specializes in manufacturing APIs, Pharma Intermediates, Specialty Chemicals, and Formulations including Ciprofloxacin Hydrochloride and Metronidazole.
Who are the competitors of Aarti Drugs?
Aarti Drugs major competitors are SMS Pharmaceuticals, Solara Active Pharma, IOL Chem & Pharma, Morepen Laboratories, Hester Biosciences, NGL Fine-Chem, Supriya Lifescience. Market Cap of Aarti Drugs is ₹3,815 Crs. While the median market cap of its peers are ₹3,351 Crs.
Is Aarti Drugs financially stable compared to its competitors?
Aarti Drugs seems to be less financially stable compared to its competitors. Altman Z score of Aarti Drugs is 4.02 and is ranked 7 out of its 8 competitors.
Does Aarti Drugs pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Aarti Drugs latest dividend payout ratio is 5.43% and 3yr average dividend payout ratio is 5.45%
How has Aarti Drugs allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Capital Work in Progress, Accounts Receivable
How strong is Aarti Drugs balance sheet?
Balance sheet of Aarti Drugs is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Aarti Drugs improving?
The profit is oscillating. The profit of Aarti Drugs is ₹191 Crs for TTM, ₹168 Crs for Mar 2025 and ₹171 Crs for Mar 2024.
Is the debt of Aarti Drugs increasing or decreasing?
The net debt of Aarti Drugs is decreasing. Latest net debt of Aarti Drugs is ₹566 Crs as of Mar-26. This is less than Mar-25 when it was ₹600 Crs.
Is Aarti Drugs stock expensive?
Aarti Drugs is not expensive. Latest PE of Aarti Drugs is 19.96, while 3 year average PE is 23.41. Also latest EV/EBITDA of Aarti Drugs is 13.14 while 3yr average is 15.4.
Has the share price of Aarti Drugs grown faster than its competition?
Aarti Drugs has given lower returns compared to its competitors. Aarti Drugs has grown at ~-0.92% over the last 4yrs while peers have grown at a median rate of 19.53%
Is the promoter bullish about Aarti Drugs?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Aarti Drugs is 54.43% and last quarter promoter holding is 55.03%
Are mutual funds buying/selling Aarti Drugs?
The mutual fund holding of Aarti Drugs is decreasing. The current mutual fund holding in Aarti Drugs is 10.08% while previous quarter holding is 10.14%.